CASI Pharma has reached a long-term agreement with a subsidiary of Shijiazhuang Yiling Pharma to manufacture two generic drugs, entecavir and cilostazol. In January of this year, CASI acquired rights to a 29-drug package of generics with abbreviated new ...


ChinaBio® Weekly Update

Contents


CASI Forms Alliance with Yiling to Manufacture Two Generics for China

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

CASI Pharma has reached a long-term agreement with a subsidiary of Shijiazhuang Yiling Pharma to manufacture two generic drugs, entecavir and cilostazol. In January of this year, CASI acquired rights to a 29-drug package of generics with abbreviated new drug applications from Sandoz, a Novartis subsidiary. CASI plans to market the drugs in China, the US and other global markets. CASI is headquartered in Maryland with R&D operations in Beijing. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:

     
 

Tot Biopharm Opens New Biologics Facility in Suzhou

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Tot Biopharm, a Suzhou oncology company, completed a monoclonal antibodies (mAb) manufacturing facility. The 13,000 square meter site will have a capacity of 16,000L when it is completely built out. Tot will use the plant for its own portfolio of oncology drugs as well as offering CDMO services to other biopharmas. The facility will offer upstream R&D, pilot-scale production, clinical trial-scale drug manufacturing and commercial production. Tot said the plant will produce both biologic drugs and small molecular drugs at commercial scale. More details....

Share this with colleagues:

     
 

Nuance Enters $58 Million Deal for Non-Opioid Pain Treatment in China

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Nuance Biotech of Shanghai in-licensed China rights to a non-opioid treatment for long-lasting pain following surgery from US-based Pacira Pharma in a $58 million agreement. Nuance will pay $3 million upfront and the rest in milestones, plus royalties. Nuance plans to file a Clinical Trial Application in China later this year. Pacira describes Exparel® (bupivacaine liposome injectable suspension) as an anesthesia deposited at the site during surgery or administered as an interscalene brachial plexus nerve block. More details....

Stock Symbol: (NSDQ: PCRX)

Share this with colleagues:

     
 

WuXi Biologics to Build $20 Million ADC Facility in Wuxi City

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

WuXi Biologics has begun construction of a $20 million state-of-the-art integrated biologics conjugate R&D/CDMO center in Wuxi city, China. The company said the 6,000 square meter facility, which will become operational in 2019, will provide a full suite of services stretching from concept to commercialization for antibody-drug conjugates (ADCs) and other protein conjugates. In the last three months, WuXi has announced five new facilities around the globe at a total cost of $812 million. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:

     
 

CStone Starts Australian Trial of MEK Inhibitor

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

CStone Pharma of Suzhou has dosed the first patient in an Australian Phase I clinical trial of CS3006, a selective small molecule inhibitor of mitogen-activated protein kinase (MEK). CS3006 is CStone's third candidate to start human testing (all of them in Australia). The others are: CS1003, a programmed death-1 (PD-1) inhibitor and CS1002, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) inhibitor. CStone plans to tests its candidates as monotherapies and combination therapies, both in China and globally. More details....

Share this with colleagues:

     
 

More Recent Articles

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.


 Not a ChinaBio®Today Subscriber?

Here's what you get with a paid subscription to ChinaBio® Today:
  • Website access to all current articles and commentary
  • Full access to over 2000 archived articles on the biotech industry

Greg B. Scott
Executive Editor
ChinaBio® Today


ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC


Safely Unsubscribe ArchivesPreferencesContactSubscribePrivacy